# Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer

> **NCT06736717** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 21 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Onvansertib
- **DRUG:** NALIRIFOX

## Key facts

- **NCT ID:** NCT06736717
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02
- **Primary completion:** 2026-07
- **Final completion:** 2027-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06736717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06736717, "Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06736717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*